SKINCEUTICALS

BLEMISH 🕂 AGE DEFENSE

As effective as the leading prescription drug for acne, BenzaClin®

OBJECTIVE

To evaluate the efficacy of SkinCeuticals Blemish + Age Defense® (OTC serum containing 1.5% salicylic acid, 3.5% glycolic acid, 2% dioic acid, and 0.3% capryloyl salicylic acid) vs. BenzaClin® (a prescription drug containing 1% clindamycin and 5% benzoyl peroxide) for the treatment of acne in subjects with mild to moderate acne.

METHODOLOGY

A single-center, split-face, double-blind, 8-week clinical trial of 28 subjects was conducted by a board-certified dermatologist.

Evaluation methods included nine-scale clinical grading for facial attributes, counting of acne lesions, subjective and objective evaluation of tolerance, and consumer self-assessment.

Primary Inclusion Criteria

- 18-40 years old
- Males and females with mild to moderate acne (at least four inflammatory lesions and seven non-inflammatory lesions on each side of the face, no cysts)

Secondary Inclusion Criteria

• Mild to moderate fine lines and wrinkles

Exclusion Criteria

Available upon request

Washout period: 7 days

PROTOCOL

Twice daily, subjects applied Blemish + Age Defense® to one side of the face and BenzaClin® to the other side. The supporting regimen was limited to a basic cleanser (Simply Clean), sunscreen (Ultimate UV Defense SPF 30), and moisturizer (Daily Moisture) to effectively evaluate the efficacy of the test products alone. Subjects were clinically evaluated at day 2, week 1, week 4, and week 8.

RESULTS

Both products were well tolerated and there was no statistically significant difference between the performance of SkinCeuticals Blemish + Age Defense® and BenzaClin® at any time.


No adverse events occurred.




Blemish + Age Defense® BenzaClin®


* Statistically significant improvement

INFLAMMATORY LESIONS




NON-INFLAMMATORY LESIONS






BLOTCHINESS



CLOGGED PORES



CONCLUSION

Blemish + Age Defense[®] is shown to be as effective as the leading prescription drug, BenzaClin[®], for the treatment of acne. As early as day 2, Blemish + Age Defense[®] significantly reduced inflammatory and non-inflammatory lesions. During the 8-week period, Blemish + Age Defense[®] also significantly reduced blotchiness and clogged pores.

At no point during the 8 weeks was there a statistically significant difference between the Blemish + Age Defense® and BenzaClin®.

ADDITIONAL RESULTS ON AGING

In a separate dermatologist-controlled clinical study of 50 subjects, Blemish + Age Defense® went beyond efficiently treating acne to correct signs of aging including hyperpigmentation, fine lines, and wrinkles.

8 Weeks Results

- Improved fine lines by 40%
- Improved brightness by 45%
- Improved smoothness by 46%